
2148 MRD Study reaches milestone with First Patient In (FPI)
4 Aug 2025

EORTC in the spotlight at ASCO 2025
4 Jun 2025

EORTC’s presence at ASCO 2025
28 May 2025

New study confirms link between cancer patients’ quality of life and survival
1 Apr 2025

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 Dec 2024

New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024

EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023

Results of two EORTC studies have been published in NEJM and the Lancet Oncology
21 Sep 2022